Indication intelligence, analysis and sector perception

VistaGen (VSTA) secures worldwide commercial rights to three stem cell technologies

December 23, 2015 8:51am

New Licenses expand drug rescue programs related to heart and liver disease and Osteoarthritis

OTCQB: VSTA has secured exclusive worldwide commercial rights to three patent-pending stem cell technologies from University Health Network (UHN), Canada's largest research hospital.

The newly licensed technologies relate to the development of stem cells into heart, liver and cartilage cells for multiple potential commercial applications, including drug rescue and regenerative therapies for heart disease, liver disease and osteoarthritis.

VistaGen now holds a total of five licenses to stem cell technologies developed in collaboration with UHN, the McEwen Centre and Dr. Keller.

The Bottom Line: These latest licensing agreements will be instrumental to its core drug rescue programs to explore collaborative opportunities.

VSTA closed DOWN -$0.08 to $6.19

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.